Karimi Galougahi, Keyvan
Shlofmitz, Evan
Jeremias, Allen
Gogia, Shawnbir
Kirtane, Ajay J.
Hill, Jonathan M.
Karmpaliotis, Dimitri
Mintz, Gary S.
Maehara, Akiko
Stone, Gregg W.
Shlofmitz, Richard A.
Ali, Ziad A. http://orcid.org/0000-0002-2482-3197
Article History
Accepted: 18 January 2021
First Online: 5 March 2021
Declarations
:
: Keyvan Karimi Galougahi: none. Evan Shlofmitz: consultant—Abbott Vascular, Opsens Medical. Allen Jeremias: institutional funding (unrestricted education grant) and serves as a consultant for Volcano/Philips and Abbott Vascular; consultant to ACIST Medical and Boston Scientific. Shawnbir Gogia: none. Ajay J. Kirtane: institutional funding to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, and ReCor Medical. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for speaking engagements and/or consulting; no speaking/consulting fees were personally received. Personal: travel expenses/meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Chiesi, OpSens, Zoll, and Regeneron. Jonathan M. Hill: personal fees grants and equity in Shockwave Medical, personal fees and grants from Abbott Vascular, personal fees and grants from Boston Scientific, and personal fees and grants from Abiomed. Dimitri Karmpaliotis: honoraria—Abiomed, Abbott Vascular, Boston Scientific; equity: Saranas, Soundbite, Traverse Vascular. Gary S. Mintz: honoraria—Boston Scientific, Philips, Terumo, and Medtronic. Akiko Maehara: grant support from Abbott Vascular and Boston Scientific, consultant for Conavi Medical Inc. Gregg W. Stone: speaker or other honoraria from Cook, Terumo, QOOL Therapeutics, and Orchestra Biomed; consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, Cardiomech; equity/options from Ancora, QOOL Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. Richard A. Shlofmitz: speaker—Shockwave. Ziad A. Ali: institutional research grants to Columbia University—Abbott, Cardiovascular Systems Inc.; consultant—Abbott, Abiomed, AstraZeneca, Shockwave.
: This article does not contain any studies with human or animal subjects performed by any of the authors.